case_images: PMC9467805_01
case_images: Abdominal computed tomography revealing a cirrhotic liver with 3 partial lipiodol-staining masses at left hepatic lobe with remaining viable part, size 3.7 x 2.9 cm at segment III (viable part at anteroinferior aspect), 4.5 x 4.4 cm at segment IVb (viable part at right posterolateral aspect), and 2.7 x 2.5 cm at segment II (small viable part at posterior aspect) in axial and coronal view of arterial phase (a-b) and axial and coronal view of portovenous phase (c-d), respectively.
case_images: CRIHEP2022-5101856.001.jpg
case_images: PMC9467805_01_CRIHEP2022-5101856.001.jpg
case_images: fig1
case_images: CT at 1-month follow-up after TACE demonstrated a viable tumor 3.1 x 2.9 cm at hepatic segment V (Figure 1).
case_images: Chest X-rays revealing moderate amount of right pleural effusion with pressure effect caused trachea shift to the left (a) and complete resolution of right pleural effusion after discontinuing lenvatinib for 1 week (b).
case_images: CRIHEP2022-5101856.002.jpg
case_images: PMC9467805_01_CRIHEP2022-5101856.002.jpg
case_images: fig2
case_images: Chest X-ray (CXR) showed moderate right pleural effusion (Figure 2(a)). One week after discontinuation of lenvatinib and supportive therapy, the patient symptoms gradually improved with a reduction of right pleural effusion (Figure 2(b)) and lowering of the urine protein creatinine ratio (UPCR) from 9.7 to 5.6 g/day after 2 weeks.